Abstract: Objective：To discuss the immune regulation mechanism of Puerarin in patients with premature ovarian failure (POF), and to study the antiovary antibody (AoAb), antinuclear antibody（ANA）, CD3+, CD4+, CD8+ T lymphocyte cell and CD4+/CD8+ and changes of CD19+B lymphocyte cell before and after treatment. Methods：Totally 40 POF cases with AoAb positive, treated with Puerarinprogesterone sequential treatment, were random selected. The clinical efficacy was analyzed before treatment and at the 12th cycle of treatment by using Kupperman, and the AoAb, CD3+, CD4+, CD8+ T cells and CD4+/CD8+, CD19+B lymphocyte cell，ANA and other indicators were recorded and analyzed. The incidence rate of adverse reactions in the treatment process was recorded. Results：Kupperman score, ANA negative rate, AoAb negative rate and concentration of antibody after treatment were significantly decreased (P＜0.05). The CD8+ T cell counts increased significantly, while the CD3+ , CD4+ T cells, CD4+/CD8+, CD19+B lymphocytes were significantly reduced after treatment (P＜0.05). Kupperman score was positively correlated with the number of AoAb, CD3+, CD4+T cells, CD19+B cell count, and ANA (P＜0.05), and negative correlated with CD8+T cell count (P＜0.05). Conclusions：Puerarinprogesterone sequential treatment is a safe and effective method for the POF. Puerarin may regulate immune function through the CD3+, CD4+ and CD8+T cells, eliminate the immune injury of the POF by inhibiting the CD19+B cell, and secretion of ANA and AoAb to realize the selfrepairing and functional recovery of ovarian.